The Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, and its Chief of Neurology, Rany Aburashed, D.O., are the first in the U.S. to use Neurofilament Light Chain testing prospectively for patients with multiple sclerosis. The study, aimed at 1,000 patients will use the technology to investigate biomarkers and predictors of MS and eventually, how these may be used to predict the progression of the disease and the effectiveness of treatments.
"NfL has the potential to dramatically increase our ability to assess disease activity and change in real time. Previous testing of NfL was limited to spinal fluid only, which remains impractical in the clinical setting. We are optimistic that this testing can hopefully help us determine the degree of underlying structural damage occurring from a condition. In turn, we hope we can also assess whether our treatments are effectively working using NfL," said Dr. Aburashed.
Read more here: Michigan-based Memorial Healthcare: First in U.S. to use new Neurofilament Light Chain technology for multiple sclerosis patients